Last 12 months
Inside the activity.
2 purchase rows · 112 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 1 | 0 |
| Dec 2025 | 0 | 2 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 1 | 2 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 26 |
| Jun 2026 | 0 | 13 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 56 |
| Sep 2026 | 0 | 12 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 05, 2020 Filed Feb 7, 2020 22:49 UTC |
Febbo Phillip G.SVP Chief Medical Officer
|
GrantCommon Stock | 1,249 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-004396 · form4.xml · nonDerivative · entry 1 Febbo Phillip G. · CIK 0001649245 · SVP Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,755 F1 · shares: Grant of restricted stock units shall vest as follows: 25% of the shares subject to the award shall vest on each of February 5, 2021, February 5, 2022, February 5, 2023 and February 5, 2024, subject to awardee's continuing status as a service provider on such dates. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 22:47 UTC |
deSouza Francis ADirector · President and CEO
|
GrantPerformance Shares · Derivative | 24,971 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-004392 · form4.xml · derivative · entry 2 deSouza Francis A · CIK 0001520943 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,971 Underlying: Common Stock · 24,971 shares Expires 2023-01-01 F3 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 1, 2023. The number of shares issued will range from 0% to 150% of the amount specified above, based on the company's actual earnings per share for the fiscal year ending January 1, 2023, relative to pre-defined objectives, subject to awardee's continuing status as a service provider on such dates. F3 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 1, 2023. The number of shares issued will range from 0% to 150% of the amount specified above, based on the company's actual earnings per share for the fiscal year ending January 1, 2023, relative to pre-defined objectives, subject to awardee's continuing status as a service provider on such dates. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 22:47 UTC |
deSouza Francis ADirector · President and CEO
|
GrantCommon Stock | 8,324 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-004392 · form4.xml · nonDerivative · entry 1 deSouza Francis A · CIK 0001520943 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,041 F1 · shares: Grant of restricted stock units shall vest as follows: 25% of the shares subject to the award shall vest on each of February 5, 2021, February 5, 2022, February 5, 2023 and February 5, 2024, subject to awardee's continuing status as a service provider on such dates. F2 · balance_after: Balance includes 70 shares acquired through Employee Stock Purchase Plan. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 22:43 UTC |
Dadswell CharlesSVP & General Counsel
|
GrantPerformance Shares · Derivative | 5,619 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-004390 · form4.xml · derivative · entry 2 Dadswell Charles · CIK 0001575229 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,619 Underlying: Common Stock · 5,619 shares Expires 2023-01-01 F3 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 1, 2023. The number of shares issued will range from 0% to 150% of the amount specified above, based on the company's actual earnings per share for the fiscal year ending January 1, 2023, relative to pre-defined objectives, subject to awardee's continuing status as a service provider on such dates. F3 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 1, 2023. The number of shares issued will range from 0% to 150% of the amount specified above, based on the company's actual earnings per share for the fiscal year ending January 1, 2023, relative to pre-defined objectives, subject to awardee's continuing status as a service provider on such dates. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 22:43 UTC |
Dadswell CharlesSVP & General Counsel
|
GrantCommon Stock | 1,873 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-004390 · form4.xml · nonDerivative · entry 1 Dadswell Charles · CIK 0001575229 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,507 F1 · shares: Grant of restricted stock units shall vest as follows: 25% of the shares subject to the award shall vest on each of February 5, 2021, February 5, 2022, February 5, 2023 and February 5, 2024, subject to awardee's continuing status as a service provider on such dates. F2 · balance_after: Balance includes 58 shares acquired through Employee Stock Purchase Plan. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 22:19 UTC |
Gottlieb ScottDirector
|
GrantCommon Stock | 395 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-004037 · form4.xml · nonDerivative · entry 1 Gottlieb Scott · CIK 0001411359 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 395 F1 · shares: Grant of restricted stock units. 100% of the shares subject to the restricted stock unit award shall vest the date prior to the annual meeting of the company's stockholders in the year of the award, provided, in each case, that the awardee continues to serve as a director on such date. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 22:40 UTC |
SAMAD SAMSVP and CFO
|
SaleCommon Stock | 238 | $293.10 | $69,757.80 |
DisclosureSEC source: 0001127602-20-003813 · form4.xml · nonDerivative · entry 1 SAMAD SAM · CIK 0001694295 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,011 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 22:37 UTC |
RAGUSA ROBERT PSVP, Global Quality & Ops
|
SaleCommon Stock | 1,253 | $293.10 | $367,254.30 |
DisclosureSEC source: 0001127602-20-003811 · form4.xml · nonDerivative · entry 1 RAGUSA ROBERT P · CIK 0001222644 · SVP, Global Quality & Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,888 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| January 09, 2020 Filed Jan 13, 2020 21:36 UTC |
Hampton Malcolm GarretSVP Clinical Genomics Group
|
Tax withholdingCommon Stock | 326 | $334.60 | $109,079.60 |
DisclosureSEC source: 0001127602-20-001466 · form4.xml · nonDerivative · entry 1 Hampton Malcolm Garret · CIK 0001698265 · SVP Clinical Genomics Group 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,598 Read SEC document |
| January 08, 2020 Filed Jan 9, 2020 21:19 UTC |
Hoyt Aimee LSVP, Chief People Officer
|
Tax withholdingCommon Stock | 156 | $332.16 | $51,816.96 |
DisclosureSEC source: 0001127602-20-001367 · form4.xml · nonDerivative · entry 1 Hoyt Aimee L · CIK 0001727683 · SVP, Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,170 Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 21:10 UTC |
TOUSI SUSAN HSVP Product Development
|
SaleCommon Stock | 200 | $325.00 | $65,000.00 |
DisclosureSEC source: 0001127602-20-001320 · form4.xml · nonDerivative · entry 1 TOUSI SUSAN H · CIK 0001791938 · SVP Product Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,465 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 21:09 UTC |
SAMAD SAMSVP and CFO
|
Tax withholdingCommon Stock | 212 | $325.53 | $69,012.36 |
DisclosureSEC source: 0001127602-20-001319 · form4.xml · nonDerivative · entry 1 SAMAD SAM · CIK 0001694295 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,249 Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:12 UTC |
Van Oene MarkSVP Chief Commercial Officer
|
SaleCommon Stock | 400 | $331.33 | $132,532.00 |
DisclosureSEC source: 0001127602-20-001121 · form4.xml · nonDerivative · entry 2 Van Oene Mark · CIK 0001707477 · SVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,178 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:12 UTC |
Van Oene MarkSVP Chief Commercial Officer
|
SaleCommon Stock | 225 | $330.38 | $74,335.50 |
DisclosureSEC source: 0001127602-20-001121 · form4.xml · nonDerivative · entry 1 Van Oene Mark · CIK 0001707477 · SVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,578 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F2 · price: Weighted average sale price representing 225 shares sold ranging from $330.26 to $331.01 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:09 UTC |
FLATLEY JAY TDirector
|
GrantCommon Stock | 446 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-001116 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,970 F1 · shares: Grant of restricted stock units. 100% of the shares subject to the restricted stock unit award shall vest on the date of the annual meeting of the company's stockholders in the year of the award, provided, in each case, that the awardee continues to serve as a director on such date. Read SEC document |
| December 11, 2019 Filed Dec 12, 2019 21:59 UTC |
FLATLEY JAY TDirector
|
Tax withholdingCommon Stock | 3,015 | $320.57 | $966,518.55 |
DisclosureSEC source: 0001127602-19-034877 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,524 Read SEC document |
| December 10, 2019 Filed Dec 12, 2019 22:13 UTC |
OSTADAN OMEADSVP Mktg, Prod & Strat Plan
|
SaleCommon Stock | 1,200 | $326.01 | $391,212.00 |
DisclosureSEC source: 0001127602-19-034882 · form4.xml · nonDerivative · entry 1 OSTADAN OMEAD · CIK 0001642678 · SVP Mktg, Prod & Strat Plan 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,844 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F2 · balance_after: Balance reflects an increase of 3 shares. The previous balance was incorrect due to an administrative error. Read SEC document |
| December 06, 2019 Filed Dec 10, 2019 21:36 UTC |
TOUSI SUSAN HSVP Product Development
|
SaleCommon Stock | 1,000 | $325.00 | $325,000.00 |
DisclosureSEC source: 0001127602-19-034684 · form4.xml · nonDerivative · entry 1 TOUSI SUSAN H · CIK 0001791938 · SVP Product Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,665 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| December 02, 2019 Filed Dec 5, 2019 00:19 UTC |
Van Oene MarkSVP Chief Commercial Officer
|
SaleCommon Stock | 625 | $320.15 | $200,093.75 |
DisclosureSEC source: 0001127602-19-034299 · form4.xml · nonDerivative · entry 1 Van Oene Mark · CIK 0001707477 · SVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,803 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F2 · price: Weighted average sale price representing 625 shares sold ranging from $320.00 to $320.35 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| December 02, 2019 Filed Dec 5, 2019 00:25 UTC |
Dadswell CharlesSVP & General Counsel
|
SaleCommon Stock | 655 | $320.33 | $209,816.15 |
DisclosureSEC source: 0001127602-19-034301 · form4.xml · nonDerivative · entry 1 Dadswell Charles · CIK 0001575229 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,576 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F2 · balance_after: Since the date of the last ownership report, 18 shares of Illumina common stock have been transferred pursuant to a domestic relations order. The reporting person no longer reports as the beneficial owner of these securities. Read SEC document |
| November 29, 2019 Filed Dec 4, 2019 01:35 UTC |
SAMAD SAMSVP and CFO
|
SaleCommon Stock | 892 | $320.00 | $285,440.00 |
DisclosureSEC source: 0001127602-19-034199 · form4.xml · nonDerivative · entry 1 SAMAD SAM · CIK 0001694295 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,461 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| November 14, 2019 Filed Nov 18, 2019 21:33 UTC |
Febbo Phillip G.SVP Chief Medical Officer
|
SaleCommon Stock | 155 | $300.00 | $46,500.00 |
DisclosureSEC source: 0001127602-19-033040 · form4.xml · nonDerivative · entry 1 Febbo Phillip G. · CIK 0001649245 · SVP Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,506 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| November 14, 2019 Filed Nov 18, 2019 21:30 UTC |
MCGINNIS KAREN KVP, Chief Accounting Officer
|
Tax withholdingCommon Stock | 116 | $298.44 | $34,619.04 |
DisclosureSEC source: 0001127602-19-033039 · form4.xml · nonDerivative · entry 1 MCGINNIS KAREN K · CIK 0001188264 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,153 Read SEC document |
| November 05, 2019 Filed Nov 7, 2019 21:51 UTC |
Febbo Phillip G.SVP Chief Medical Officer
|
Tax withholdingCommon Stock | 83 | $300.87 | $24,972.21 |
DisclosureSEC source: 0001127602-19-032212 · form4.xml · nonDerivative · entry 1 Febbo Phillip G. · CIK 0001649245 · SVP Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,661 Read SEC document |
| November 05, 2019 Filed Nov 7, 2019 21:49 UTC |
Van Oene MarkSVP Chief Commercial Officer
|
Tax withholdingCommon Stock | 1,156 | $300.87 | $347,805.72 |
DisclosureSEC source: 0001127602-19-032210 · form4.xml · nonDerivative · entry 1 Van Oene Mark · CIK 0001707477 · SVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,428 Read SEC document |
| November 05, 2019 Filed Nov 7, 2019 21:44 UTC |
SAMAD SAMSVP and CFO
|
Tax withholdingCommon Stock | 259 | $300.87 | $77,925.33 |
DisclosureSEC source: 0001127602-19-032205 · form4.xml · nonDerivative · entry 1 SAMAD SAM · CIK 0001694295 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,353 Read SEC document |
| November 05, 2019 Filed Nov 7, 2019 21:46 UTC |
TOUSI SUSAN HSVP Product Development
|
Tax withholdingCommon Stock | 1,137 | $300.87 | $342,089.19 |
DisclosureSEC source: 0001127602-19-032206 · form4.xml · nonDerivative · entry 1 TOUSI SUSAN H · CIK 0001791938 · SVP Product Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,665 Read SEC document |
| November 05, 2019 Filed Nov 7, 2019 21:40 UTC |
OSTADAN OMEADSVP Mktg, Prod & Strat Plan
|
Tax withholdingCommon Stock | 1,644 | $300.87 | $494,630.28 |
DisclosureSEC source: 0001127602-19-032200 · form4.xml · nonDerivative · entry 1 OSTADAN OMEAD · CIK 0001642678 · SVP Mktg, Prod & Strat Plan 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,041 Read SEC document |
| November 05, 2019 Filed Nov 7, 2019 21:42 UTC |
RAGUSA ROBERT PSVP, Global Quality & Ops
|
Tax withholdingCommon Stock | 1,051 | $300.87 | $316,214.37 |
DisclosureSEC source: 0001127602-19-032201 · form4.xml · nonDerivative · entry 1 RAGUSA ROBERT P · CIK 0001222644 · SVP, Global Quality & Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,141 Read SEC document |
| November 05, 2019 Filed Nov 7, 2019 21:43 UTC |
Ronaghi MostafaSVP & CTO
|
Tax withholdingCommon Stock | 1,178 | $300.87 | $354,424.86 |
DisclosureSEC source: 0001127602-19-032203 · form4.xml · nonDerivative · entry 1 Ronaghi Mostafa · CIK 0001441876 · SVP & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,407 Read SEC document |
| November 05, 2019 Filed Nov 7, 2019 21:38 UTC |
MCGINNIS KAREN KVP, Chief Accounting Officer
|
Tax withholdingCommon Stock | 80 | $300.87 | $24,069.60 |
DisclosureSEC source: 0001127602-19-032195 · form4.xml · nonDerivative · entry 1 MCGINNIS KAREN K · CIK 0001188264 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,269 F1 · balance_after: Balance includes 109 shares acquired through Employee Stock Purchase Plan. Read SEC document |
| November 05, 2019 Filed Nov 7, 2019 21:36 UTC |
Hoyt Aimee LSVP, Chief People Officer
|
Tax withholdingCommon Stock | 99 | $300.87 | $29,786.13 |
DisclosureSEC source: 0001127602-19-032192 · form4.xml · nonDerivative · entry 1 Hoyt Aimee L · CIK 0001727683 · SVP, Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,326 F1 · balance_after: Balance includes 128 shares acquired through Employee Stock Purchase Plan. Read SEC document |
| November 05, 2019 Filed Nov 7, 2019 21:32 UTC |
FLATLEY JAY TDirector
|
Tax withholdingCommon Stock | 1,194 | $300.87 | $359,238.78 |
DisclosureSEC source: 0001127602-19-032188 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,539 Read SEC document |
| November 05, 2019 Filed Nov 7, 2019 21:35 UTC |
Hampton Malcolm GarretSVP Clinical Genomics Group
|
Tax withholdingCommon Stock | 492 | $300.87 | $148,028.04 |
DisclosureSEC source: 0001127602-19-032191 · form4.xml · nonDerivative · entry 1 Hampton Malcolm Garret · CIK 0001698265 · SVP Clinical Genomics Group 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,924 Read SEC document |
| November 05, 2019 Filed Nov 7, 2019 21:26 UTC |
deSouza Francis ADirector · President and CEO
|
Tax withholdingCommon Stock | 3,953 | $300.87 | $1,189,339.11 |
DisclosureSEC source: 0001127602-19-032179 · form4.xml · nonDerivative · entry 1 deSouza Francis A · CIK 0001520943 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,647 Read SEC document |
| November 05, 2019 Filed Nov 7, 2019 21:23 UTC |
Dadswell CharlesSVP & General Counsel
|
Tax withholdingCommon Stock | 820 | $300.87 | $246,713.40 |
DisclosureSEC source: 0001127602-19-032172 · form4.xml · nonDerivative · entry 1 Dadswell Charles · CIK 0001575229 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,249 Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 21:18 UTC |
RAGUSA ROBERT PSVP, Global Quality & Ops
|
SaleCommon Stock | 1,674 | $297.28 | $497,646.72 |
DisclosureSEC source: 0001127602-19-031882 · form4.xml · nonDerivative · entry 1 RAGUSA ROBERT P · CIK 0001222644 · SVP, Global Quality & Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,192 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 21:55 UTC |
Dadswell CharlesSVP & General Counsel
|
SaleCommon Stock | 193 | $297.28 | $57,375.04 |
DisclosureSEC source: 0001127602-19-031936 · form4.xml · nonDerivative · entry 1 Dadswell Charles · CIK 0001575229 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,069 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 21:50 UTC |
Van Oene MarkSVP Chief Commercial Officer
|
SaleCommon Stock | 625 | $300.10 | $187,562.50 |
DisclosureSEC source: 0001127602-19-031926 · form4.xml · nonDerivative · entry 1 Van Oene Mark · CIK 0001707477 · SVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,584 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F2 · price: Weighted average sale price representing 625 shares sold ranging from $300.04 to $300.20 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| October 15, 2019 Filed Oct 17, 2019 20:46 UTC |
Ronaghi MostafaSVP & CTO
|
Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $69.34 | $0.00 |
DisclosureSEC source: 0001127602-19-030734 · form4.xml · derivative · entry 6 Ronaghi Mostafa · CIK 0001441876 · SVP & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2021-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| October 15, 2019 Filed Oct 17, 2019 20:46 UTC |
Ronaghi MostafaSVP & CTO
|
SaleCommon Stock | 100 | $312.87 | $31,287.00 |
DisclosureSEC source: 0001127602-19-030734 · form4.xml · nonDerivative · entry 5 Ronaghi Mostafa · CIK 0001441876 · SVP & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,585 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| October 15, 2019 Filed Oct 17, 2019 20:46 UTC |
Ronaghi MostafaSVP & CTO
|
SaleCommon Stock | 1,394 | $311.86 | $434,738.56 |
DisclosureSEC source: 0001127602-19-030734 · form4.xml · nonDerivative · entry 4 Ronaghi Mostafa · CIK 0001441876 · SVP & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,685 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F4 · price: Weighted average sale price representing 1,394 shares sold ranging from $311.43 to $312.42 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| October 15, 2019 Filed Oct 17, 2019 20:46 UTC |
Ronaghi MostafaSVP & CTO
|
SaleCommon Stock | 1,296 | $310.74 | $402,723.19 |
DisclosureSEC source: 0001127602-19-030734 · form4.xml · nonDerivative · entry 3 Ronaghi Mostafa · CIK 0001441876 · SVP & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,079 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F3 · price: Weighted average sale price representing 1,296 shares sold ranging from $310.43 to $311.09 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| October 15, 2019 Filed Oct 17, 2019 20:46 UTC |
Ronaghi MostafaSVP & CTO
|
SaleCommon Stock | 1,210 | $309.89 | $374,961.94 |
DisclosureSEC source: 0001127602-19-030734 · form4.xml · nonDerivative · entry 2 Ronaghi Mostafa · CIK 0001441876 · SVP & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,375 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F2 · price: Weighted average sale price representing 1,210 shares sold ranging from $309.15 to $310.14 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| October 15, 2019 Filed Oct 17, 2019 20:46 UTC |
Ronaghi MostafaSVP & CTO
|
Exercise / conversionCommon Stock | 4,000 | $69.34 | $277,360.00 |
DisclosureSEC source: 0001127602-19-030734 · form4.xml · nonDerivative · entry 1 Ronaghi Mostafa · CIK 0001441876 · SVP & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,585 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| October 07, 2019 Filed Oct 9, 2019 22:42 UTC |
GOSWAMI JOYDEEPSVP Corp Business Development
|
GrantPerformance Shares · Derivative | 3,979 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-030346 · form4.xml · derivative · entry 2 GOSWAMI JOYDEEP · CIK 0001533115 · SVP Corp Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,979 Underlying: Common Stock · 3,979 shares Expires 2022-01-02 F2 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 2, 2022. The number of shares issued will range from 0% to 150% of the amount specified above, based on the company's actual earnings per share for the fiscal year ending January 2, 2022, relative to pre-defined objectives, subject to awardee's continuing status as a service provider on such dates. F2 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 2, 2022. The number of shares issued will range from 0% to 150% of the amount specified above, based on the company's actual earnings per share for the fiscal year ending January 2, 2022, relative to pre-defined objectives, subject to awardee's continuing status as a service provider on such dates. Read SEC document |
| October 07, 2019 Filed Oct 9, 2019 22:42 UTC |
GOSWAMI JOYDEEPSVP Corp Business Development
|
GrantCommon Stock | 1,327 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-030346 · form4.xml · nonDerivative · entry 1 GOSWAMI JOYDEEP · CIK 0001533115 · SVP Corp Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,327 F1 · shares: Grant of restricted stock units with 25% of the shares subject to the award vesting on each of the first, second, third and fourth anniversaries of the date of grant, subject to the awardee's continuing to be a service provider on such dates. Read SEC document |
| October 01, 2019 Filed Oct 3, 2019 20:24 UTC |
Dadswell CharlesSVP & General Counsel
|
SaleCommon Stock | 124 | $304.22 | $37,723.28 |
DisclosureSEC source: 0001127602-19-030013 · form4.xml · nonDerivative · entry 1 Dadswell Charles · CIK 0001575229 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,262 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| October 01, 2019 Filed Oct 3, 2019 20:26 UTC |
Van Oene MarkSVP Chief Commercial Officer
|
SaleCommon Stock | 625 | $304.84 | $190,525.00 |
DisclosureSEC source: 0001127602-19-030015 · form4.xml · nonDerivative · entry 1 Van Oene Mark · CIK 0001707477 · SVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,209 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F2 · price: Weighted average sale price representing 625 shares sold ranging from $304.64 to $304.95 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| September 16, 2019 Filed Sep 18, 2019 21:03 UTC |
Ronaghi MostafaSVP & CTO
|
Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $69.34 | $0.00 |
DisclosureSEC source: 0001127602-19-028752 · form4.xml · derivative · entry 6 Ronaghi Mostafa · CIK 0001441876 · SVP & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 10,000 shares Expires 2021-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.